Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, phase II, multi-center clinical trial. Subjects can only
enter this study after they meet the inclusion and exclusion criteria. All enrolled patients
will receive the treatment with anti-PD-1 combined with albumin-bound paclitaxel, every 3
weeks, until progressive disease, initiation of new anti-tumour therapy, death, intolerable
toxicity. Albumin-bound paclitaxel may be used for up to 6 cycles and anti-PD-1 for up to 2
years.